Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in
≡ List 

Disease ⇒ Breast cancer ⇒ Cancer {40000376}

Record Keys

Breast cancer


Initialisation date:[  ]
Other Terms:[  ]

Meta Information

MedDra ID:
MedDra Level:
ICD:[  ]
Category:[  ]
Zone:[  ]
Mechanism:[  ]


[  ]

References Notes

[  ]

Shared Reference Notes

  • [1.8
    - Cadaverine as a biogenic amine is formed through the direct decarboxylation of L-lysine.
    - It is reported that cadaverine biosynthesis is reduced in the gut in early-stage BC, resulting in lower production of an anti-cancer bacterial metabolite and reduced BC invasion
  • - Lithocholic acid can inhibit BC progression, epithelial-mesenchymal transition, and metastasis via activation of nuclear factor erythroid 2-related factor 2 (NRF2) and other proteins involved in the antioxidant defense system.
  • - Propionate, acetate, and butyrate are the three most predominant SCFAs and are well-known modulators for cell invasion and apoptosis in BC
  • - The abundance of Akkermansia muciniphila, as a key player of propionate production, is associated with the richness of the gut microbiota in patients with BC
  • - Intestinal bacteria can turn some plant lignans such as flaxseed, sunflower, caraway, pumpkin, legumes, and soybean, into mammalian lignans with protective effects against BC.
    - High consumption of raw vegetables showed a significant protective effect against BC risk.
  • - Enterolactone may act as a selective modulator of estrogen signaling and may be associated with lowering the risk of BC.
  • - Overuse of antibiotics might reduce the plasma level of lignan enterolactone; therefore, it might directly affect the microbiome populations and increase the BC risk
  • - Estrobolome, the bacterial gene mass in the human intestine, the products of which take part in estrogens metabolism, may increase the risk of estrogen receptor-positive BC in postmenopausal females.
    - Changes in gut microbiome composition may lead to the estrogen metabolism alternation and affect the BC risk.
  • - The proportions of Blautia and F. Prausnitzii and absolute numbers of Blautia and Bifidobacterium species in the gut microbiome are directly correlated with the clinical stage of BC.
    - For instance, patients with stage 1 BC had a lower number of gut Blautia sp. in comparison with the ones with stage grade 3
  • [1.9
    - Antibiotic-induced perturbation of the gut microbiota > increases tumor progression in multiple BrCa mouse models > increased number of cells with a stromal signature in tumors > increased abundance of mast cells in the tumor stromal regions.
    - Re-supplementation of antibiotic-treated mice with Faecalibaculum rodentium > restored tumor growth to control levels
    - Mast cell stabilizer, cromolyn > decreases tumor growth only in antibiotic treated animals
  • [1.11
    - Fucoidan > increasing the diversity of the intestinal flora composition and increasing the Bacteroidetes/Firmicutes phylum ratio > can restore intestinal wall damage in mice > prevent the occurrence of breast cancer
  • - H2S at a safe and nontoxic concentration can protect not only healthy cells, such as neurons, but also cancerous cells from apoptosis.
    - In a variety of cancers, including ovarian cancer, oral cancer, thyroid cancer, colon cancer, breast cancer, etc., the upregulation of H2S-producing enzyme CBS > can enhance the proliferation ability of cancer cells and make cancer cells more sensitive to it
  • [1.12
    - Permutation testing with FDR control revealed taxa differences for fat% in Firmicutes, Bacilli, Bacillales, Staphylococcaceae and genus Staphylococcus, and fibrosis% in Firmicutes, Spirochaetes, Bacilli, Bacillales, Spirochaetales, Proteobacteria RF32, Sphingomonadales, Staphylococcaceae, and genera Clostridium, Staphylococcus, Spirochaetes, Actinobacteria Adlercreutzia.

Common References